tiprankstipranks
Trending News
More News >
I-Mab Adr (IMAB)
:IMAB
US Market

I-MAB (IMAB) AI Stock Analysis

Compare
337 Followers

Top Page

IM

I-MAB

(NASDAQ:IMAB)

Rating:45Neutral
Price Target:
The overall stock score of 45 reflects I-MAB's substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
Positive Factors
Clinical Data
Clinical data for Givastomig shows an 83% overall response rate, which is favorable compared to the approximately 40% response rate of a competitor's treatment.
Enrollment Progress
Enrollment in the Givastomig dose expansion cohorts is ahead of schedule, indicating strong interest and potential progress in the study.
Safety Profile
Givastomig continues to demonstrate a differentiated and manageable safety profile, with no dose-limiting toxicities or grade 4/5 TRAEs, and only isolated grade 3 events.
Negative Factors
Financial Resource Limitations
I-Mab recently announced it will be prioritizing its remaining resources on givastomig, a CLDN18.2x4-1BB bispecific antibody.
Resource Allocation
I-Mab is halting further clinical development of uliledlimab in NSCLC.

I-MAB (IMAB) vs. SPDR S&P 500 ETF (SPY)

I-MAB Business Overview & Revenue Model

Company DescriptionI-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.
How the Company Makes MoneyI-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royalties from these partnerships as its drug candidates progress through clinical trials and reach the market. Additionally, I-MAB might gain revenue from licensing its proprietary technologies and intellectual property to other entities. Significant partnerships with global pharmaceutical companies facilitate the advancement of its pipeline, contributing to its earnings potential.

I-MAB Financial Statement Overview

Summary
I-MAB faces substantial financial challenges, particularly in terms of profitability and cash flow generation. Although the company benefits from a strong liquidity position and low leverage, its ability to generate positive earnings and cash flows remains a concern. The volatility in revenue and consistent losses highlight the need for strategic adjustments to improve financial performance.
Income Statement
20
Very Negative
The company's income statement indicates significant challenges, with substantial negative net income and EBIT margins over recent years. Although there was a positive revenue figure in 2023, the revenue growth has been erratic, with a substantial decline from 2020 to 2022 followed by a modest recovery. Gross profit margins have been inconsistent, which, coupled with negative net profit and EBIT margins, underscores profitability issues.
Balance Sheet
50
Neutral
The balance sheet shows a strong equity base relative to liabilities, with a debt-to-equity ratio remaining low due to minimal debt levels. However, the equity ratio has been declining, indicating diminishing equity relative to total assets. The company maintains a significant cash position, which is a positive sign of liquidity.
Cash Flow
30
Negative
Cash flow analysis reveals persistent negative free cash flows, indicating challenges in generating sufficient cash from operations. The absence of operating cash flow data for 2023 makes it difficult to assess the recent cash generation ability. Historical trends show negative operating cash flow, impacting the overall cash flow position negatively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.99M0.0027.64M-221.56M88.03M1.54B
Gross Profit3.99M0.0027.64M-248.80M41.59M1.54B
EBITDA-303.56M-373.45M-1.21B-1.94B-2.06B168.31M
Net Income-341.81M-162.26M-1.47B-2.51B-2.33B470.92M
Balance Sheet
Total Assets232.68M212.68M2.61B4.07B5.63B6.33B
Cash, Cash Equivalents and Short-Term Investments184.39M173.40M2.29B3.45B4.28B4.79B
Total Debt3.78M3.88M18.89M74.99M112.45M13.60M
Total Liabilities14.80M11.52M894.81M1.07B1.04B706.65M
Stockholders Equity217.88M201.16M1.72B3.01B4.59B5.63B
Cash Flow
Free Cash Flow0.00-52.72M-72.86M-1.15B-1.00B425.55M
Operating Cash Flow0.00-52.67M-72.70M-1.10B-973.09M433.56M
Investing Cash Flow0.00-136.01M102.52M458.38M-727.21M-201.90M
Financing Cash Flow0.00-335.00K7.57M42.36M593.92M3.44B

I-MAB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.29
Price Trends
50DMA
1.56
Positive
100DMA
1.21
Positive
200DMA
1.15
Positive
Market Momentum
MACD
0.23
Positive
RSI
53.66
Neutral
STOCH
36.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMAB, the sentiment is Positive. The current price of 2.29 is below the 20-day moving average (MA) of 2.43, above the 50-day MA of 1.56, and above the 200-day MA of 1.15, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 53.66 is Neutral, neither overbought nor oversold. The STOCH value of 36.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMAB.

I-MAB Risk Analysis

I-MAB disclosed 91 risk factors in its most recent earnings report. I-MAB reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We face significant risks related to the transition of our business focus to the U.S. market and our business and prospects may be materially and adversely affected. Q4, 2023
2.
We face risks associated with the divestiture of the Greater China assets and business operations to I-Mab Hangzhou. Q4, 2023
3.
Evolvement in the U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. Q4, 2023

I-MAB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$12.79B11.4722.69%25.11%46.46%
56
Neutral
$3.88B-32.05%43.72%28.63%
ONONC
54
Neutral
$30.72B-11.44%51.16%50.65%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
46
Neutral
$130.68M-49.23%105.85%22.13%
45
Neutral
$184.72M-22.38%
42
Neutral
$1.15M
-95.23%-325.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMAB
I-MAB
2.29
0.69
43.13%
FATE
Fate Therapeutics
1.12
-2.05
-64.67%
AFMDQ
Affimed
0.05
-4.97
-99.00%
ONC
BeOne Medicines
244.32
97.28
66.16%
ZLAB
Zai Lab
35.49
18.17
104.91%
GMAB
Genmab
20.44
-5.10
-19.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 31, 2025